Published in Cancer Weekly, May 25th, 2004
According to published research from the United States, "irinotecan is a topoisomerase I inhibitor previously shown to be active in the treatment of malignant glioma (MG). We now report the results of a phase 1 trial of irinotecan plus BCNU, or 1,3-bis(2-chlorocthyl)-1-nitrosourea, for patients with recurrent or progressive MG. Irinotecan dose escalation occurred independently within 2 strata: patients receiving enzyme-inducing antiepileptic drugs (EIAEDs) and patients not receiving EIAEDs.
"BCNU was administered at a dose of 100 mg/m2 over 1 hour every 6 weeks on...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.